Commenting on the H1 2017 results, Hilde Windels, interim Chief Executive Officer Biocartis (until 31 August 2017), said that the company’s first half 2017 performance is best characterized by the 195% growth realized year-over-year in commercial product revenues.
Windels said that this shows that the company’s investments in menu and geographical expansion successfully translated into higher commercial volumes, demonstrating the adoption of the Idylla(TM) platform in the current markets.
“We are thrilled to start selling in the US market in the second half of this year and look forward to important tests launches in the coming months. This will put us in an excellent position to continue this impressive growth curve. I am confident that under the leadership of Herman Verrelst, our new CEO as of 1 September, Biocartis will also continue to deliver on its promises to globally impact the way molecular diagnostics is performed,” said Windels.
The company reported net result of -€23,982,000, compared to 2016’s -23,784,000, which represents change of 1%.